Table 1. Immunophenotypic markers in T-PLL.
| Matutes (1) | Chen (2)a | Garant (9)b | Garant (9)c | |||||
|---|---|---|---|---|---|---|---|---|
| Immunophenotype | Number of cases tested | % positive | Number of cases tested | % positive | Number of cases tested | % positive | Number of cases tested | % positive |
| CD1a | 55 | 0 | 11 | 0 | 38 | 3 | 13 | 0 |
| CD2 | 77 | 99 | 29 | 100 | 53 | 100 | 18 | 94 |
| CD3 | 68 | 81 | 29 | 89.7 | 53 | 94 | 19 | 89 |
| CD5 | 27 | 100 | 29 | 100 | 51 | 100 | 18 | 100 |
| CD7 | 56 | 93 | 29 | 100 | 46 | 93 | 14 | 93 |
| CD4+CD8− | 72 | 65 | 29 | 37.9 | 53 | 60 | 19 | 74 |
| CD4+CD8+ | 72 | 21 | 29 | 41.4 | 53 | 17 | 19 | 24 |
| CD4-CD8+ | 72 | 13 | 29 | 17.2 | 53 | 15 | 19 | 0 |
| CD4-CD8- | 72 | 1 | 29 | 3.4 | 53 | 8 | 19 | 6 |
| CD25 | 44 | 18 | 17 | 35.3 | 33 | 15 | 10 | 20 |
| CD38 | 33 | 52 | 17 | 53 | 10 | 20 | ||
| HLA-DR | 52 | 8 | 41 | 0 | 11 | 9 | ||
| CD10 | 23 | 0 | 34 | 3 | 15 | 0 | ||
| CD16 | 10 | 0 | ||||||
| CD34 | 27 | 0 | ||||||
| CD45 | 29 | 93.1 | ||||||
| CD52 | 19 | 100 | ||||||
| CD56 | 29 | 0 | 30 | 3 | 11 | 0 | ||
| TdT | 22 | 0 | ||||||
| Tαβ+ | 25 | 60 | 23 | 96 | 11 | 82 | ||
| Tγδ+ | 23 | 0 | 11 | 0 | ||||
| CD45RO+ CD45RA- | 18 | 83 | 10 | 10 | ||||
| CD45RO- CD45RA+ | 18 | 11 | 10 | 40 | ||||
| CD45RO+ CD45RA+ | 18 | 6 | 10 | 10 | ||||
| CD45RO- CD45RA- | 18 | 10 | 10 | 40 | ||||
a29 population subsets analyzed among 20 cases; binitially aggressive forms; cinitially indolent forms.